OS Therapies (OSTX) Non Operating Income (2023 - 2026)
OS Therapies' (OSTX) quarterly Non Operating Income came in at -$228893.0 in Q1 2026, down 120.39% YoY from $1.1 million in Q1 2025, and up 84.46% on a QoQ basis from -$1.5 million in Q4 2025.
OS Therapies (OSTX) Non Operating Income (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Non Operating Income data on file, last reported at -$228893.0 in Q1 2026.
- Quarterly Non Operating Income fell 120.39% year-over-year to -$228893.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.4 million (down 1089.16% YoY) and the FY2025 annual result came in at -$48143.0, up 97.67% from the prior year.
- Non Operating Income rose to -$228893.0 in Q1 2026, from -$1.5 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $1.1 million in Q1 2025 to a low of -$1.5 million in Q4 2025.
- A 4-year average of -$445774.1 and a median of -$437839.0 in 2024 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 235.46% in 2025, down 5836.88% in 2025.
- Tracing OSTX's Non Operating Income over 4 years: stood at -$307534.0 in 2023, then soared by 91.93% to -$24810.0 in 2024, then sank by 5836.88% to -$1.5 million in 2025, then soared by 84.46% to -$228893.0 in 2026.
- The last three Non Operating Income figures came in at -$228893.0 (Q1 2026), -$1.5 million (Q4 2025), and $65.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | OS Therapies | 19.46 Mn | 19.46 Mn | - | -56,774.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -228,893.00 |
| Dec 31, 2025 | -1.47 Mn |
| Sep 30, 2025 | 65.00 |
| Jun 30, 2025 | 302,106.00 |
| Mar 31, 2025 | 1.12 Mn |
| Dec 31, 2024 | -24,810.00 |
| Sep 30, 2024 | -437,839.00 |
| Jun 30, 2024 | -777,680.00 |
| Mar 31, 2024 | -828,760.00 |
| Dec 31, 2023 | -307,534.00 |
| Sep 30, 2023 | -1.35 Mn |
| Jun 30, 2023 | -989,684.00 |
| Mar 31, 2023 | -798,938.00 |